Groundbreaking remote robotic surgery: Patient was in Africa; doctor was in Florida
Fernando da Silva, who lives in the southern African nation of Angola, was diagnosed with prostate cancer in March.
Three months later, he underwent a procedure to cut out the cancer from a surgeon who has done tens of thousands of similar procedures.
But the doctor performing the surgery was 7,000 miles away -- in Orlando, Florida.
MORE: Doctors save baby's life with first-ever gene fix for deadly rare disease
Da Silva was the first patient of a groundbreaking human clinical trial approved by the U.S. Food and Drug Administration to test transcontinental robotic telesurgery.
"We've been working on this really for two years," Dr. Vipul Patel, the medical director of the Global Robotic Institute at Orlando's Advent Health, told ABC News after completing the surgery. "We traveled the globe, looking at the right technologies."
ABC News' medical correspondent Dr. Darien Sutton was granted exclusive access to the remote surgery in a special report that aired June 16 on ABC News Live Prime with Linsey Davis.
Prostatectomy, a surgical procedure that removes part or all the prostate, has more recently been done with a sophisticated robotic surgery system.
Instead of scrubbing into the operating room, surgeons operate on patients via a multimillion-dollar robot with enhanced visuals and nimble controls.
MORE: Kraft Heinz to remove artificial dyes from food products over next 2 years
Using a robot allows for the procedure to be less invasive, more precise and typically comes with a faster recovery time.
While surgeons are typically near the patient they are operating on, Patel and his team were eager to test whether the surgery could be done long distance using a fiber optic cables.
"I think the humanitarian implications are enormous," Patel said. "Internationally, obviously, there's so many underserved areas of the world."
Patel also pointed out that rural areas within the U.S. could benefit by helping surgeons learn new procedures from a distance or helping patients from a distance if complications arise during surgery.
"Emergency room physicians will have technology that can be remotely accessible to surgeons, maybe even in the ambulance, where people can get remote interventions if they can't make it to the hospital," Patel said.
Patel had his surgical team in the operating room in Angola and were prepared for any potential issues, in case they arose.
"We made sure we had plan A, B, C, and D. I always have my team where the patient is," Patel said. "So, in case something happened with" the telecommunications, "the team would just take over and finish the case and do it safely."
Patel said he plans to submit the data from the surgery back to the FDA for teams there to review in the hopes he will be able to do more telesurgeries.
"It was a small step for a surgeon, but it was huge leap for health care," he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
What is rabies, how to avoid it and how to recognise the symptoms?
Rabies is a rare and serious infection that affects the brain and the nervous system, so it is important to be aware of information about it. Human cases of rabies are very rare in the UK, but it poses a risk to travellers visiting regions where the disease remains prevalent. While the risk is still small, rabies is more common in parts of Asia, Africa, Central America and South America. Here's all you need to know about the infection, including how to recognise symptoms and how to avoid it. If you're travelling to a country where rabies is present, it's worth knowing how to reduce your risk - read our blog post for more info. 🔗 — UK Health Security Agency (@UKHSA) June 18, 2025 According to the NHS website, rabies is spread by mammals, such as dogs, bats, raccoons and foxes. You can get rabies if you're bitten or scratched by an infected animal. Additionally, it can be passed on if an infected animal licks your eyes, nose or mouth, or you have a wound that's licked by an infected animal. Rabies symptoms usually take between three to 12 weeks to appear, but they can also occur within a few days or take several months or years. Symptoms of the infection include: numbness or tingling where you were bitten or scratched seeing things that are not there (hallucinations) feeling very anxious or energetic difficulty swallowing or breathing being unable to move (paralysis) Once symptoms develop in an infected person after they have been exposed, it is almost always fatal. The UK Health Security Agency (UKHSA) says you need to take a number of immediate steps if you believe you have been in contact with a rabies-infected animal. You should wash the wound with plenty of soap and water for several minutes to reduce the risk of infection. Additionally, seek local medical attention without delay, as treating it sooner will be more effective. They add: "Contact your GP on return to the UK, even if you received post-exposure treatment abroad or the exposure happened several weeks ago. "You may need to continue a course of rabies vaccines. If you have a record of any treatment given, remember to bring this with you." According to the NHS website, the level of protection varies, but a full course should last one or two years. People who are travelling to areas with a risk of rabies more than a year after their course of vaccines can have a single booster dose. If you're travelling to a region where there is a chance of rabies, you need to take preventative measures. The UKHSA recommends consulting a travel health professional before your trip. Recommended reading: Person dies in Yorkshire from rabies after contact with a stray dog in Morocco How long do colds last and how can you cure them quickly? Urgent Mounjaro and Ozempic warning for anyone planning a holiday They can determine if pre-exposure vaccination is recommended based on your destination and planned activities. The UKHSA adds: "Vaccination is particularly important if you'll be staying for over a month, engaging in outdoor activities, or travelling to areas with limited access to medical care." It is also advised to avoid contact with animals as much as possible when travelling.
Washington Post
13 hours ago
- Washington Post
His custom cancer therapy is in an NIH freezer. He may not get it in time.
Richard Schlueter, 56, was planting cucumbers and squash in his community garden plot in Greensboro, Georgia, in May when he tore open a bag of soil and heard a pop. His collarbone had snapped. In early June, a scan revealed that the cancer that started in his tonsils was racing through his bones. That day, he called a medical team at the National Institutes of Health that had created an experimental cell therapy, custom-made to attack his cancer as part of a clinical trial. He needed it. Now. Instead, he received more bad news: His therapy would be delayed at least a month because of staff cuts at NIH. A week later, Schlueter and his wife, Michelle, saw NIH Director Jay Bhattacharya push back on concerns raised by his own staff that the ouster of essential employees and other disruptions to the biomedical research agency were harming science and patients. Bhattacharya said on X that objections raised in a document called the Bethesda Declaration contained 'fundamental misconceptions' about NIH's new direction. Each termination was being reviewed, and some workers were reinstated, he added. But the Schlueters had a front-row seat to the effects of the job losses. Richard's therapy was in a freezer, nearly ready to go. All along, they had been told the final step of preparation takes three to four weeks. But on June 3, his NIH doctor informed him that it would now take eight to 10 weeks because of cuts to essential lab personnel — a painful illustration of the life-and-death stakes of the administration's approach to shrinking the government workforce. 'I'm petrified. I have to do something,' Richard said. 'My cancer is on the move.' The Washington Post first reported in early April that the production of specialized immune-cell therapies for metastatic cancer patients was delayed. Two highly skilled technicians who prepared cells for treatments were fired in the probationary purge in February, according to Steven Rosenberg, an NIH immunotherapy pioneer who leads multiple trials. He declined to say how many patients were affected, but his team now treats one patient per week, down from two or three before the cuts. 'There are some patients who might have to wait until September,' Rosenberg said. 'These are all patients with metastatic cancer that is progressive. You can imagine the difficulty as we have to tell them these things.' An official with the Department of Health and Human Services, which oversees NIH, said the agency had ways of addressing the delays. Rosenberg has been granted permission to hire contractors or to request help from other scientists from across NIH, said the official, who spoke on the condition of anonymity to criticize an employee. Rosenberg said he has been working urgently to try to rehire a scientist who was fired since he was given permission to do so last week, but the federal contracting process is slow and the scientist has been interviewing for other jobs. He noted that to prepare the cells for patients requires special training that takes four to six months. Richard's cancer nightmare started with what he thought was acid reflux. A few weeks after his annual physical in January 2024, he noticed a metallic taste in the back of his throat. Looking in the bathroom mirror, he saw little white pustules on one of his tonsils. A scan and biopsy showed it was head and neck squamous cell carcinoma, but an oncologist told him it was treatable, with an excellent chance of success. Unless it spread. On Richard's 55th birthday, March 11, 2024, he began chemotherapy and proton therapy. He had always taken good care of his health and was diligent with his treatments. But a scan in July revealed that the cancer had spread to his lungs and part of his chest cavity. 'It was heart-wrenching, and it was difficult,' said Richard, a founding partner of an Atlanta law firm. 'I'm a fact-finder, and I spend a lot of time researching and trying to find a path to remission or a potential cure. And it's a pretty bleak outlook.' Richard's efforts led him to NIH, where he felt blessed to qualify for a trial led by Rosenberg. Doctors would take a biopsy of his cancer and find and isolate immune cells called TIL, tumor-infiltrating lymphocytes. They would use lab tests to select the cells that recognized Richard's cancer and expand the population. Then, they would reinfuse them into his body. There are no guarantees with clinical research. Patients who qualify for the trial have exhausted standard treatments. But it gave the Schlueters something they had been missing: hope. 'Patients often refer to us not as the National Institutes of Health, but the National Institutes of Hope,' Rosenberg said. In January, Richard went to NIH for surgery to remove two tumors in his lungs and begin the process of isolating and testing the TIL cells. He read the NIH credo — to improve the human condition throughout the world — emblazoned on a wall of the Clinical Center and was so moved that he sent a photo of it to his three children. 'The staff, the physicians, the amount of empathy, care and mission that I've experienced over four visits to their research hospital has been just super gratifying,' Richard said. 'In many ways, I'm a guinea pig that may be helping other people. But I also have the byproduct that if it works, it will help me.' In late March, Richard returned to NIH, thinking it was go time. Instead a scan showed that the tumors in his lungs had unexpectedly become smaller. He returned home, knowing his therapy would be ready in the freezer if he took a turn for the worse. Rosenberg's team meets every Monday to discuss patient cases, and for months they have had to make difficult calls to seriously ill people. Richard is just one. Natalie Phelps, a mother of two from Bainbridge Island, Washington, with metastatic colorectal cancer, is waiting for cells in another of Rosenberg's trials. This one uses a different form of immunotherapy, but it is also slowed because of the loss of critical personnel. Last Friday, she gave The Post an update: 'So frustrating. I should be having treatment now, but instead I had to restart chemo and will be returning to start the treatment process' in late July. Two scientists on Rosenberg's team who have specialized skills to prepare cells for immunotherapy trials were among the thousands of probationary employees fired in the Trump administration's push to shrink the federal workforce. The one who would have finalized Richard's infusion had worked at NIH since 2020 and was recently hired as a full-time employee because she was considered so effective, according to Rosenberg. But that made her vulnerable, as a probationary employee with fewer protections. Rosenberg is trying to hire her back on contract using nongovernment funding. Richard is an optimist. His biggest fear is not qualifying for the experimental immune cells that he hopes could beat back his cancer. Doing nothing isn't an option because his cancer is spreading rapidly. Radiation might buy him time but leave his white blood cell count too low to be eligible for the trial. Robert L. Ferris, a head and neck surgical oncologist at the University of North Carolina Lineberger Comprehensive Cancer Center, said patients such as Richard have tough and tragic cases where standard medical care has been exhausted. Ferris is not involved in Richard's care, but the doctor said the trajectory of a cancer like this is grim. It is unlikely the cell therapy will cure Richard, Ferris cautioned, but science progresses through individual cases like his. And if Richard is forced to wait too long, he could be too frail to try it. 'If the cells are ready, you would want to give it to him now,' Ferris said. In mid-May, Richard was golfing with his nephew and his son. He was running, swimming, biking and lifting weights. The only sign something was awry was a red rash on his face that resembled a sunburn, a side effect of one of his treatments. But as the cancer has spread through his bones, his arms have become weak, and he has a suspected microfracture in his right arm. Pain in a hip makes it hard to get out of a chair. The Schlueters' 30th wedding anniversary celebration in early June was a joyous occasion, but Richard struggled to walk down the aisle to renew their vows. Even if the therapy doesn't save Richard, his family hopes his experience can help others. 'If he misses [it], not only is it is it devastating for his family, but it's devastating for all the patients behind him that could have learned something scientifically — on why it was successful or not successful,' Michelle said. 'He's like a test pilot.'
New York Times
14 hours ago
- New York Times
A Cutting-Edge Cancer Therapy Offers Hope for Patients With Lupus
Jennifer Le's doctor ticked through a long checklist of head-to-toe symptoms as she examined Ms. Le in a Boston clinic last month. Was she experiencing brain fog? Headaches? What about hair loss, rashes or joint pain? Ms. Le, 36, was diagnosed with lupus in 2016, just after she got married. She tried all the standard treatments, hoping that her symptoms would stabilize and she could one day get pregnant. Pregnancy wasn't possible on the medications she needed to tamp down the inflammation causing her arthritis and anemia. And it was too dangerous to try for a baby with uncontrolled lupus, a chronic disease that causes the body to attack its own healthy tissue. By last fall, Ms. Le had run out of conventional treatment options. That's when Dr. Meghan Sise, her physician, offered her a chance to participate in a clinical trial that was testing a new therapy, borrowed from the field of cancer research. 'Let's try it,' Ms. Le told Dr. Sise, who is a principal investigator on the trial. 'I have nothing to lose.' CAR T-cell therapy, a kind of 'living drug' that modifies patients' immune cells to help them attack misbehaving ones, has been used with significant success to treat some cancers, particularly of the blood. A growing body of evidence has suggested that the therapy can also treat a severe form of lupus that, at best, can be managed as a lifelong condition and, at worst, resists treatment and can lead to organ failure and death. 'It's really promising, and honestly the first therapy that we've talked about as a cure,' said Dr. Lisa Sammaritano, a rheumatologist at the Hospital for Special Surgery — Weill Cornell Medicine and the lead author on a set of recently updated guidelines for lupus treatment. Until now, she said, 'we haven't had a cure — we've had control.' Want all of The Times? Subscribe.
